Dyne Therapeutics, Inc.
830 Winter Street
Waltham, MA 02451
September 14, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Laura Crotty
Re: Dyne Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-248414
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Dyne Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-248414), as amended, so that it may become effective at 4:00 p.m. Eastern time on September 16, 2020, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request by telephone call to the staff of the U.S. Securities and Exchange Commission. Please contact Stuart M. Falber of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Company, at (617) 526-6663, or in his absence, Jeffries L. Oliver-Li at (617) 526-6786 or Scott N. Lunin at (212) 295-6388, to provide notice of effectiveness, or if you have any other questions regarding this matter.
[Remainder of Page Intentionally Left Blank]
| Very truly yours, | ||
| DYNE THERAPEUTICS, INC. | ||
| By: | /s/ Joshua Brumm | |
| Name: | Joshua Brumm | |
| Title: | President and Chief Executive Officer | |